These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30231682)

  • 21. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?
    Mason A; Drummond M; Ramsey S; Campbell J; Raisch D
    J Clin Oncol; 2010 Jul; 28(20):3234-8. PubMed ID: 20498408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Development of the Romanian Scorecard HTA System.
    Radu CP; Chiriac ND; Pravat AM
    Value Health Reg Issues; 2016 Sep; 10():41-47. PubMed ID: 27881276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Costs and benefits of improving access to psychotherapies for common mental disorders.
    Dezetter A; Briffault X; Ben Lakhdar C; Kovess-Masfety V
    J Ment Health Policy Econ; 2013 Dec; 16(4):161-77. PubMed ID: 24526585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health Economics in the Field of Prosthetics and Orthotics: A Global Perspective.
    Kannenberg A; Seidinger S
    Can Prosthet Orthot J; 2021; 4(2):35298. PubMed ID: 37615010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pricing and reimbursement of drugs in Sweden.
    Lundkvist J
    Eur J Health Econ; 2002; 3(1):66-70. PubMed ID: 15609120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pricing and reimbursement of pharmaceuticals in Sweden.
    Jönsson B
    Pharmacoeconomics; 1994; 6 Suppl 1():51-60. PubMed ID: 10172482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of reimbursement restriction on drug market sales under the National Health Insurance in Japan.
    Mamiya H; Igarashi A
    J Med Econ; 2022; 25(1):206-211. PubMed ID: 35060813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan.
    Jirawattanapisal T; Kingkaew P; Lee TJ; Yang MC
    Value Health; 2009; 12 Suppl 3():S4-11. PubMed ID: 20586980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current national initiatives about drug policies and cost control in Europe: the Italy example.
    Rocchi F; Addis A; Martini N;
    J Ambul Care Manage; 2004; 27(2):127-31. PubMed ID: 15069990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What can the Canadians and Americans learn from each other's health care systems?
    Weil TP
    Int J Health Plann Manage; 2016 Jul; 31(3):349-70. PubMed ID: 27469581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
    Vogler S; Vitry A; Babar ZU
    Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review.
    Parkinson B; Sermet C; Clement F; Crausaz S; Godman B; Garner S; Choudhury M; Pearson SA; Viney R; Lopert R; Elshaug AG
    Pharmacoeconomics; 2015 Sep; 33(9):905-24. PubMed ID: 26048353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. List prices and clinical value of anticancer drugs in China, Japan, and South Korea: a retrospective comparative study.
    Pan J; Wei X; Lu H; Wu X; Li C; Hai X; Lan T; Dong Q; Yang Y; Jakovljevic M; Zhou J
    Lancet Reg Health West Pac; 2024 Jun; 47():101088. PubMed ID: 38774422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.
    Maniadakis N; Kourlaba G; Shen J; Holtorf A
    BMC Health Serv Res; 2017 May; 17(1):371. PubMed ID: 28545440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A NEW HEALTH TECHNOLOGY ASSESSMENT SYSTEM FOR JAPAN? SIMULATING THE POTENTIAL IMPACT ON THE PRICE OF SIMEPREVIR.
    Mahlich J; Kamae I; Rossi B
    Int J Technol Assess Health Care; 2017 Jan; 33(1):121-127. PubMed ID: 28560939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
    Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
    JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.